- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00542763
Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome
Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome - An Open Label Pilot Trial
Primary Sjogren's syndrome (pSS) is an autoimmune disorder characterized by keratoconjunctivitis sicca and xerostomia. In addition, various extraglandular manifestations may develop. Several immunomodulating agents have been attempted in the treatment of pSS without achieving satisfactory results. Currently, there is no approved systemic treatment for pSS.
Mycophenolic acid (MPA) is a selective inhibitor of inosine-monophosphate-dehydrogenase which leads to inhibition of the de novo pathway of nucleotide synthesis. The antiproliferative effect of MPA mainly affects activated T- and B-lymphocytes because the proliferation of these cells is critically dependent on the de novo purine synthesis compared to other eukaryotic cells. Since these lymphocytes have been suggested to play a pivotal role in the inflammation and immunopathogenesis of pSS, mycophenolate-sodium might be a promising agent in the treatment of pSS.
We perform a single-centre, open-label pilot trial with Mycophenolate sodium in pSS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mycophenolic acid containing compounds such as mycophenolate mofetil and enteric coated mycophenolate sodium are immunosuppressive drugs approved for the prevention of transplant rejection. Mycophenolate mofetil (MMF) is an effective treatment in systemic lupus erythematosus and other autoimmune diseases.
MMF has been used as maintenance therapy after treatment with rituximab (anti-CD20 antibody) in a pSS patient. We have reported a case of successful treatment with MMF in pSS with vasculitis.
The recent observations and the immunosuppressive effect of MPA in other autoimmune diseases led us to evaluate the efficacy and safety of MPA treatment in patients with pSS refractory to other immunosuppressive agents.
The observation period will be 6 months. At baseline, after 3, and after 6 months we examine the clinical status including glandular function tests as well as different laboratory parameters associated with pSS. In addition subjective parameters will be determined on the basis of different questionnaires.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
NRW
-
Muenster, NRW, Germany, 48129
- University Hospital Muenster
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of primary Sjogren' Syndrome based on the American-European Consensus criteria
- Erythrocyte sedimentation rate >25mm/h and hypergammaglobulinemia (>1500 mg/dl)
- Presence of anti-SS-A and /or SS-B antibodies and / or rheumatoid factor
- Requirement of artificial teardrops due to symptomatic sicca syndrome
- Inadequate response or intolerance of prior treatment with hydroxychloroquine and / or azathioprine
- Adequate contraception for females of childbearing potential
Exclusion Criteria:
- Age below 18 or above 75 years
- Secondary Sjogren's syndrome
- History of cancer, severe infections or other uncontrolled diseases
- Treatment with concomitant disease modifying anti-rheumatic drugs within the least 8 weeks before baseline evaluation
- Prednisolone dose of > 5mg/d or changes of prednisolone dose within the least 4 weeks before baseline
- Use of secretagogues (e.g. pilocarpine, cevimeline) or medications that potentially diminish exocrine gland function (e.g. tricyclic antidepressants, anti-cholinergic drugs)
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of mycophenolate sodium for sicca syndrome and changes in laboratory values associated with the disease
Time Frame: Basline, week 12 and week 24
|
Basline, week 12 and week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of mycophenolate sodium in patients with primary Sjogren's syndrome: Clinical examination, full blood count, renal function tests, liver function tests
Time Frame: basline, after week 4, 12, and week 24
|
basline, after week 4, 12, and week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Markus Gaubitz, MD, University Hospital Muenster
Publications and helpful links
General Publications
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8. doi: 10.1136/ard.61.6.554.
- Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol. 2006 May;2(5):252-61. doi: 10.1038/ncprheum0165.
- Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus. 1999;8(9):731-6. doi: 10.1191/096120399678840927.
- Willeke P, Schotte H, Schluter B, Erren M, Becker H, Dyong A, Mickholz E, Domschke W, Gaubitz M. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis. 2003 Apr;62(4):359-62. doi: 10.1136/ard.62.4.359.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Mycophenolic Acid
Other Study ID Numbers
- myf-01-049
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Sjogren's Syndrome
-
The Cleveland ClinicBristol-Myers SquibbWithdrawnRheumatoid Arthritis | Inflammatory Arthritis | Primary Sjogren's Syndrome | Secondary Sjogren's SyndromeUnited States
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Stanford UniversityWithdrawnPrimary Sjogren's Syndrome
-
Matthew C. BakerWithdrawnPrimary Sjogren's SyndromeUnited States
-
Keio UniversityUnknown
-
Pontificia Universidad Catolica de ChileFormulario MAgistral Farmacias AhumadaCompletedXerostomia | Primary Sjogren | Secondary SjogrenChile
-
Shanghai University of Traditional Chinese MedicineRecruitingInterstitial Lung Disease | Primary Sjogren's SyndromeChina
-
argenxIqvia Pty LtdRecruitingPrimary Sjögren's SyndromeBelgium, Hungary, Poland
-
Assistance Publique - Hôpitaux de ParisRecruitingPrimary Sjögren's Syndrome (pSS)France
-
Peking University People's HospitalRecruitingPrimary Sjögren's SyndromeChina
Clinical Trials on Mycophenolate sodium
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States
-
Irmandade Santa Casa de Misericórdia de Porto AlegreNovartisCompleted
-
University of PennsylvaniaNovartis PharmaceuticalsTerminatedTransplants and ImplantsUnited States
-
NovartisCompletedMaintenance Kidney TransplantSwitzerland
-
Novartis PharmaceuticalsCompleted
-
University of MiamiNovartis PharmaceuticalsCompleted
-
Klemens BuddeNovartis PharmaceuticalsCompletedImmunosuppression | Transplantation | Drug InteractionGermany
-
NovartisCompletedKidney TransplantationBrazil
-
Novartis PharmaceuticalsActive, not recruitingLupus NephritisTaiwan
-
Cedars-Sinai Medical CenterNovartis PharmaceuticalsCompletedHeart Transplantation | Gastrointestinal SymptomsUnited States